High levels of circulating CD34+/VEGFR3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 7, 2013, Pages 1268-1275

  Qiu, Huiling ^a   Cao, Lili ^a   Wang, Dan ^a   Xu, Huicheng ^a   Liang, Zhiqing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Lymph node metastasis; Lymphangiogenesis; Lymphatic vascular endothelial progenitor cell

Indexed keywords

CD34 ANTIGEN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOMETRIUM CANCER; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC VASCULAR ENDOTHELIAL PROGENITOR CELL; MEASUREMENT; OVARY CARCINOMA; PROTEIN BLOOD LEVEL;

ADULT; ADULT STEM CELLS; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOLOGICAL MARKERS; BONE MARROW CELLS; COHORT STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LYMPHATIC METASTASIS; LYMPHOID PROGENITOR CELLS; MIDDLE AGED; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84880270692     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12047     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Roett MA, Evans P. Ovarian cancer: An overview. Am Fam Physician 2009; 80: 609-616.
3. Naora H, Montell DJ. Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355-366.
4. Benedet J, Bender H, Jones H et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262.
5. Desteli GA, Gultekin M, Usubutun A et al. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature. World J Surg Oncol 2010; 8: 106-111.
6. Rubatt JM, Darcy KM, Hutson SM et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 469-474.
7. Palmer JE, Sant Cassia L, Irwin CJ et al. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol 2007; 26: 395-403.
8. Religa P, Cao R, Bjorndahl M et al. Presence of bone marrowderived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 2005; 106: 4184-4190.
9. Bogos K, Renyi-Vamos F, Dobos J et al. High VEGFR-3- positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res 2009; 15: 1741-1746.
10. Su Y, Zheng L, Wang Q et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res 2010; 29: 27-33.
11. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med 2005; 56: 79-101.
12. Kerjaschki D, Huttary N, Raab I et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 2006; 12: 230-234.
13. Döme B, Hendrix MJ, Paku S et al. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007; 170: 1-15.
14. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006; 94: 1355-1360.
15. Stacker SA, Achen MG, Jussila L et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-583.
16. Salven P, Mustjoki S, Alitalo R et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 168-172.
17. Jackson DG. Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis. Cancer Treat Res 2007; 135: 39-53.
18. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol 2007; 25: 4298-4307.
19. Ran S, Volk L, Hall K et al. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010; 4: 229- 251.
20. Su JL, Yen CJ, Chen PS et al. The role of theVEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007; 96: 541-545.
21. Fukunaga S, Maeda K, Noda E et al. Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology 2006; 71: 204-211.
22. Tsirlis TD, Kostakis A, Papastratis G et al. Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. J Surg Oncol 2010; 102: 699-703.
23. Tanaka T, Ishiguro H, Kuwabara Y et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010; 29: 83-89.
24. Yang H, Kim C, Kim MJ et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 2011; 10: 36-47.
25. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
26. Scotton CJ, Wilson JL, Scott K et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-5938.
27. Sasaki K, Natsugoe S, Ishigami S et al. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep 2009; 21: 65-71.
28. Reckamp KL, Figlin RA, BurdickMDet al. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer 2009; 9: 213-221.
29. Yoon Y, Liang Z, Zhang X et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007; 67: 7518-7524.
30. Tan CT, Chu CY, Lu YC et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 2008; 29: 1519-1527.